| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802688901017 | 268890101 | REMODULIN SOL.INF 1mg/ML BTx 1VIAL x 20ML | 2346.54 | 2381.79 | 2594.13 |
| 05/2018 | 2802688902014 | 268890201 | REMODULIN SOL.INF 2,5mg/ML BT x 1VIAL x 20ML | 5150.17 | 5227.42 | 5651.89 |
| 05/2018 | 2802688903011 | 268890301 | REMODULIN SOL.INF 5mg/ML BT x 1VIAL x 20ML | 9096.37 | 9232.81 | 9982.52 |
| 05/2018 | 2802688904018 | 268890401 | REMODULIN SOL.INF 10mg/ML BT x 1VIAL x 20ML | 18067.16 | 18338.17 | 19827.23 |
For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
* 14 L/70 kg